Published in Pain and Central Nervous System Week, October 7th, 2002
In addition, Roche and Memory will develop compounds within the same drug class for other indications, such as depression. The first drug candidate represents a novel approach and shows promising features compared with existing therapies for Alzheimer's disease. It is scheduled to enter human clinical trials in the near future.
Memory's compounds will complement Roche's neurology portfolio, and the collaboration will also broaden efforts in discovery of drug treatments for psychiatric...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pain and Central Nervous System Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.